XVA and Counterparty Exposure Stabilisation Director

The mandate

An interim leader is required to stabilise exposure and valuation-adjustment analytics whose daily output is available but whose lineage, exception ownership and cross-measure reconciliation are not sufficiently dependable. The assignment begins with live diagnosis, proceeds through risk-ranked correction and ends after an internal successor proves command of the controls. It does not operate trading, set limits or replace approved valuation policy.

In the first fifteen working days, the Director will trace representative netting sets through market data, trade population, collateral terms, exposure simulation and adjustment aggregation. Authority includes pausing unsupported manual overrides, setting daily issue priorities, requiring source owners to correct failed inputs and escalating material production uncertainty. Reserved methodology and reported valuation conclusions remain with designated executives.

The recovery must distinguish exposure-model weakness from legal-agreement interpretation, input quality, computational failure and accounting presentation. Particular attention will go to wrong-way risk, collateral and margin timing, funding and capital components, close-out assumptions, proxy use and unexplained movement between daily runs. Each exception needs consequence, owner and verified closure evidence.

By month four, the critical production chain should operate with controlled inputs, version evidence, reconciliation thresholds and a transparent limitation register. Two internal candidates will then alternate daily command, investigate deliberately seeded faults and present the resulting risk assessment without relying on the interim’s private knowledge.

Exit is conditional on three stable monthly cycles, an accepted methodology-to-output map, a recovery playbook and successful successor simulation. The remit excludes methodology redevelopment beyond approved fixes, legal opinion, limit setting, pricing ownership, infrastructure replacement and permanent hiring. Calendar extension cannot substitute for delayed knowledge transfer.

What you will own

• Map the end-to-end exposure and valuation-adjustment chain, including populations, netting, collateral, simulation, aggregation and reporting.
• Rank defects by financial consequence, recurrence, detectability and dependence on manual intervention.
• Establish controlled market-data, trade, agreement and model-version intake with clear fallback and escalation rules.
• Reconcile major adjustment movements to portfolio, parameter, methodology, market and implementation drivers.
• Govern overrides and proxies through documented purpose, quantitative impact, approval, expiry and replacement plan.
• Deliver three monthly cycles without unexplained material exposure or adjustment movements crossing approved thresholds.
• Test two internal successors using seeded input, netting and computational exceptions under reporting time pressure.
• Record out-of-scope redesign needs separately while preserving the stabilisation timetable.

Candidate qualifications

• Demonstrate interim command of counterparty exposure and XVA production at methodology-to-control depth.
• Describe an unexplained adjustment movement you decomposed and the defect ultimately corrected.
• Show working knowledge of CVA, DVA, FVA, capital or margin adjustments and their data dependencies.
• Evidence resolution of a netting, collateral or wrong-way-risk issue involving quantitative and legal facts.
• Provide metrics for stability that went beyond successful completion of the production run.
• Explain how you maintained decision boundaries among model, valuation, risk and legal owners.
• Show a successor-led live or simulated cycle that proved the recovered process no longer depended on you.

Working terms and boundaries

• The ten-month engagement requires five days each week and covers diagnosis, correction, three proof cycles and transfer.
• Day rates include on-site production leadership and normal peak intensity; extraordinary travel needs written approval.
• The Director controls recovery and evidence gates but cannot set limits, approve legal interpretations or own reported valuation.
• Infrastructure replacement, broad redevelopment, permanent recruitment and trading decisions are excluded.
• A two-month extension requires a documented failure of the successor production test despite timely management participation.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 6 October 2026. Mandate reference QNT-INT-2026-SIN-02.